Jeffrey Brent

Add links
Source: Wikipedia, the free encyclopedia.
Jeffrey A. Brent
University of Colorado Health Sciences Center
ThesisThe toxicity of 5-bromo 2'-deoxyuridine to malignant lymphoid cells (1978)

Jeffrey A. Brent is a medical toxicologist

methanol and ethylene glycol poisoning, and he led a trial of this drug which resulted in the FDA approving it in December 1997.[5]
Currently, Brent serves as Director of the Toxicology Investigators Consortium, an NIH and FDA supported multi center research and surveillance group. Brent is also a senior editor of "Critical Care Toxicology: Diagnosis and Management of the Critically Poisoned Patient," originally published in 2005, and now in its second edition, which was published in 2017.

Education

In 1970, Brent graduated from

Denver Health Medical Center, a residency at Emory University and an internship at Beth Israel Deaconess Medical Center.[6]

Career

He was initially appointed to the University of Colorado in 1987 as an instructor, and then was promoted to assistant professor, then associate, then full, and finally to distinguished professor. He has authored more than 200 peer-reviewed publications. He was the chair of the toxicology section of the American College of Emergency Physicians from 1991 to 1993. Brent has published many scientific studies, primarily in the area of medical toxicology.

Brent was one of the U.S. government's experts in the

autism
, and that the signs and symptoms of autism are very different from those of ethylmercury poisoning.

Testimony

In the so-called autism omnibus trial, Brent testified on behalf of the government, i.e. that thimerosal does not cause autism. In particular, he criticized the concept of hypersensitivity to thimerosal as a concept that had been invoked as a way to bypass real science. He also testified that, with regard to the levels of mercury in the urine of Jordan King and William Mead, who had been chelated, that "You always expect to see levels in the urine bump post-chelation." He also criticized the plaintiff's use of Doctor's Data Laboratories as relying on urine mercury levels rather than the gold standard, blood mercury levels.[8] Brent has also voiced opposition to the use of chelation therapy as an autism treatment both in the omnibus trial, where he testified that "there was absolutely no reason to chelate them [the children who served as the test cases] for any mercury-related reason," and in peer-reviewed journals.[9][10]

Selected publications

References

  1. ^ "American College of Medical Toxicology Newsletter". American College of Medical Toxicology. Spring 2009. Archived from the original (newsletter) on 7 June 2010. He [Brent] is one of about 250 board-certified medical toxicologists in the United States, and he has experience in treating children with actual mercury toxicity.
  2. ^ "Clinical Pharmacology and Toxicology". University of Colorado. Retrieved 3 August 2013.
  3. ^ "Environmental and Occupational Health". Colorado School of Public Health. Archived from the original on 16 July 2014. Retrieved 5 August 2013.
  4. University of Colorado Health Sciences Center. 27 May 2010. Archived from the original
    on May 27, 2010. Retrieved 3 August 2013.
  5. ^ Leary, Warren E. (23 March 1999). "Antidote for Pretty Poison Is Found, but at Big Price". The New York Times. Retrieved 6 November 2013.
  6. HealthGrades
    . Retrieved 4 August 2013.
  7. S2CID 7639936
    .
  8. ^ "Green Our Vaccines Eve – Dr Jeffrey Brent". LeftBrainRightBrain. 3 June 2008. Retrieved 8 August 2013.
  9. PMID 24113859
    .
  10. ^ Tsouderos, Trine (22 November 2009). "Risky alternative therapies for autism have little basis in science". Chicago Tribune. Retrieved 6 November 2013.

External links

Retrieved from "https://en.wikipedia.org/w/index.php?title=Jeffrey_Brent&oldid=1144293105"